Efficacy and Safety of Imetelstat in ESA- ineligible patients

Opinion
Video

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      • Please discuss the efficacy and safety findings from IMerge in patients for patients who have sermon EPO levels >500m U/L (ESA ineligible):
      • IMerge (Platzbecker et al. Lancet 2024) (Santini et al. EHA 2024, Abstr. S184)
      • MEDALIST (Fenaux et al. NEJM 2020) (Santini et al. ASH 2023, Abstr. 915)
      Recent Videos
      1 expert is featured in this series.
      Next-Generation Approaches and Future Directions in PV Care
      1 expert is featured in this series.
      Advanced Therapeutic Algorithms for PV Treatment Sequencing
      Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches
      Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches
      Advances in MPN Management: Insights From MANIFEST-2 and Beyond
      Advances in MPN Management: Insights From MANIFEST-2 and Beyond
      Ongoing studies of Ra-223–based combinations
      Ongoing studies of Ra-223–based combinations
      1 expert in this video
      Academic Perspectives on Systemic Therapy for Advanced uHCC
      2 experts in this video
      Considerations for Treatment Approaches in Intermediate-Stage HCC
      2 experts in this video
      Navigating the Evolving First-Line Treatment Regimens in Intermediate-Stage HCC
      Protecting bone health for patients receiving Ra-223 + ARPI combination
      Protecting bone health for patients receiving Ra-223 + ARPI combination
      1 expert in this video
      Optimizing Frontline TKI Therapy in Advanced uHCC: Managing Adverse Events
      Related Content
      Phase 3 Trial of the ArteraAI Prostate Test Begins Enrollment

      Phase 3 Trial of the ArteraAI Prostate Test Begins Enrollment

      Jordyn Sava
      March 16th 2025
      Article

      The first patient has been enrolled in the PROSTATE-IQ trial of ArteraAI, a multimodal artificial intelligence biomarker test.

      Read More

      Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

      Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

      Nichole Tucker
      June 30th 2023
      Podcast

      In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

      Listen

      First Patient Dosed in Phase 1/2 Trial of HLD-0915 for mCRPC

      First Patient Dosed in Phase 1/2 Trial of HLD-0915 for mCRPC

      Jordyn Sava
      March 5th 2025
      Article

      A phase 1/2 trial is evaluating HLD-0915, a novel oral therapy, for metastatic castration-resistant prostate cancer in up to 80 patients.

      Read More

      First Patient Dosed With IO-108 in Phase 1b/2 HCC Trial

      First Patient Dosed With IO-108 in Phase 1b/2 HCC Trial

      Jordyn Sava
      March 3rd 2025
      Article

      A global, randomized, phase 1b/2 trial is evaluating IO-108 in patients with metastatic and/or unresectable hepatocellular carcinoma.

      Read More

      First Patient Dosed in IB-T101 ccRCC Trial

      First Patient Dosed in IB-T101 ccRCC Trial

      Jordyn Sava
      February 27th 2025
      Article

      IB-T101, a CD70-targeted chimeric antigen receptor therapy, is being studied for relapsed clear cell renal cell carcinoma treatment in a dose-escalation trial.

      Read More

      First Patient Dosed in Study of Iadademstat Combo in MDS

      First Patient Dosed in Study of Iadademstat Combo in MDS

      Jordyn Sava
      February 26th 2025
      Article

      The first patient with myelodysplastic syndrome has received iadademstat plus azacitidine in a phase 1 trial at the Medical College of Wisconsin.

      Read More